Clinical trials: Hematologic
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Leukemia
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01005368
- Testing
- fluorescence in situ hybridization, mutation analysis, nucleic acid sequencing
- Where
- 35 sites in United States
- Volunteers
- 600 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hemophilia B
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
The Study's Primary Objective is to evaluate the pharmacokinetics, safety (acute effects associated with infusions, and inhibitor development) and efficacy (breakthrough bleeding and control of hemorrhaging during prophylaxis) of…
- Trial name
- NCT01271868
- Testing
- IB1001
- Where
- 10 sites in United States, India and 1 more
- Volunteers
- 9 people
- Sponsor
- Medexus Pharma, Inc.
Hematologic Malignancy, Stem Cell Transplant Complications
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
- Trial name
- NCT05921318
- Testing
- Beijing protocol
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Crohn's Disease
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease
- Trial name
- NCT00152490
- Testing
- Certolizumab Pegol (CDP870)
- Volunteers
- 604 people
- Sponsor
- UCB Pharma
Blood Disease, Cerebrovascular Accident
Stroke Prevention in Sickle Cell Anemia (STOP 2)
To determine how long blood transfusions are needed for primary stroke prevention. Also, to determine the duration of risk associated with abnormal transcranial Doppler ultrasound (TCD) and to determine the specificity of the…
- Conditions
- Blood Disease, Cerebrovascular Accident, Anemia, Sickle Cell
- Trial name
- NCT00006182
- Testing
- Blood Transfusion
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Blastic Plasmacytoid Dendritic Cell Neoplasm
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm.
- Trial name
- NCT04216524
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:
To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD) inducing higher complete remission (CR) rate, in untreated primary ALL adult patients with VDCLD regimen induction therapy.
- Trial name
- NCT02070523
- Testing
- VDCLD regimen
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
Chronic Lymphocytic Leukemia
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
To investigate limited course of treatment of Zebutinib combined with immunochemotherapy for patients with newly treated chronic lymphocytic leukemia without 17p-/TP53 mutation
- Trial name
- NCT04980859
- Testing
- Zebutinib&BR or Zebutinib&FCR
- Volunteers
- 45 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Thrombocytopenia
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
Purpose: To evaluate the efficacy and safety of rHuTPO/rHuIL-11 in the treatment for chemotherapy-induced thrombocytopenia in patients with NSCLC receiving gemcitabine and cisplatin or carboplatin chemotherapy.
- Trial name
- NCT02344979
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Osteoporosis, Osteonecrosis
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
This study explores the effect of zoledronic acid on incident vertebral fractures and osteonecrotic lesions in children recently diagnosed with acute lymphoblastic leukemia.
- Conditions
- Osteoporosis, Osteonecrosis, Acute Lymphoblastic Leukemia
- Trial name
- NCT02632903
- Testing
- Zoledronic acid
- Where
- Canada
- Sponsor
- Children's Hospital of Eastern Ontario
Myeloproliferative Neoplasms
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
The purpose of this study is to test the safety and tolerability of ruxolitinib at different dose levels in combination with decitabine and the effectiveness of ruxolitinib in combination with decitabine in patients with…
- Trial name
- NCT02076191
- Testing
- Ruxolitinib, Decitabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- John Mascarenhas
Iron-deficiency, Anemia
Iron-Biofortified Rice Intervention in the Philippines
The objective of this randomized efficacy feeding trial was to determine the effects of consuming iron-biofortified rice on iron status in women, compared to non-biofortified rice.
- Trial name
- NCT04623918
- Testing
- Iron-biofortified rice, Control rice
- Where
- Philippines
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Cornell University
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Von Willebrand Disease
Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease
The objectives of this study are to evaluate the immediate tolerability and safety of rVWF:rFVIII in subjects with Type 3 Von Willebrand Disease after administration of various dosages of VWF:RCo.
- Trial name
- NCT00816660
- Testing
- Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 32 people
- Sponsor
- Baxalta now part of Shire
Severe Aplastic Anemia, Platelet Transfusion Refractoriness
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR).
- Trial name
- NCT06254560
- Testing
- Rituximab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Thrombocytopenia, Purpura, Thrombocytopenic
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
It is a translational research study with mechanistical objectives and including biological samples of patients with thrombocytopenia
- Conditions
- Thrombocytopenia, Purpura, Thrombocytopenic, Myelodysplastic Syndromes
- Trial name
- ICTUS (NCT04003220)
- Testing
- blood sample, Bone marrow sample
- Where
- 4 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Myeloma Multiple, Metastatic Bone Tumor
CTFEA Myeloma Study
Patients with Multiple Myeloma are monitored for disease progression and for response to treatment by the treating hematologist or oncologist. Laboratory tests are usually utilized for these purposes.
- Trial name
- NCT04364724
- Testing
- CT-based finite element analysis
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases…
- Trial name
- ELLIPSE (NCT01507480)
- Testing
- Bevacizumab
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Severe Aplastic Anemia
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
Hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA) -matched donor is an effective option for severe aplastic anemia (SAA), but there is no standardized and recommended conditioning regimen.
- Trial name
- NCT06069180
- Testing
- Busulfan, Flu/Cy/ATG or Cy/ATG
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.